Shanghai issues new biopharma measures tied to access and urgent-use imports

Shanghai's English policy release on July 1 says the city introduced 25 measures to support major foreign-invested biopharmaceutical projects across research, manufacturing and headquarters functions.

For medical-travel watchers, the most relevant points are operational rather than promotional. The notice says eligible already-marketed Class II medical devices can move through technical review faster, imported drugs will receive integrated customs and sampling support, and small quantities of clinically urgent drugs or medical devices with overseas registration may be temporarily imported according to law for specific medical purposes at designated medical institutions.

This does not mean broad patient access is automatic. International patients should still confirm directly with the licensed hospital and treating team whether a specific product can legally be used, what approvals are needed, how long logistics may take and what costs are not covered.